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Abstract
Aims/hypothesis This study evaluates the pharmacodynamic
and pharmacokinetic properties of thenovelultra-fast insulin
product VIAject, a formulation of human soluble insulin and
generally recognised as safe ingredients designed to increase
the rate of absorption.
Methods We performed five euglycaemic glucose clamps
(Biostator; target blood glucose 5 mmol/l) in ten healthy
volunteers. Using a crossover design with a fixed treatment
order, 12 IU human soluble insulin, 12 U insulin lispro and
12 IU ultra-fast insulin were injected s.c. in the abdominal
region on three study days. On the other two study days,
6 and 3 IU ultra-fast insulin were injected.
Results Subcutaneous injection of 12 IU ultra-fast insulin
resulted in a time–action profile characterised by an even
more rapid onset of action and maximal metabolic activity
than insulin lispro: time to early half-maximal activity was
33±17 min (mean±SD) vs insulin lispro 51±13 min vs
human soluble insulin 66±15 min (p<0.05 ultra-fast
insulin<insulin lispro<human soluble insulin); time to
maximal activity was 136±56 min vs insulin lispro 152±
30 min vs human soluble insulin 193±57 min (p<0.05
ultra-fast insulin and insulin lispro<human soluble insulin).
The metabolic activity in the first 2 h after injection was
higher with ultra-fast insulin and insulin lispro than with
human soluble insulin (AUC glucose infusion rate [GIR]
0–120 min: 915±301 and 781±174 vs 580±164 mg/kg;
p<0.05). A clear dose–response relationship was observed
with the three doses of ultra-fast insulin: AUCGIR 0–
120 min 12 IU 915±301 vs 6 IU 718±255 vs 3 IU 524±
262 mg/kg (p<0.05). The pharmacokinetic data confirmed
the pharmacodynamic results.
Conclusions/interpretation This study shows that the onset
of action of VIAject is faster than that of human soluble
insulin and insulin lispro.
Keywords Insulintherapy.Prandial insulin.
Rapid-actinginsulinanalogues
Abbreviations
AUCGIR AUC of glucose infusion rate
AUCINS AUC of insulin concentration
Cmax maximum insulin
concentration
GIR glucose infusion rate
GIRmax maximum GIR
tCmax time to Cmax
tGIRmax time to GIRmax
Introduction
Rapid-acting insulin analogues were developed [1] to meet
prandial insulin requirements more effectively. Rather than
altering the primary structure of the insulin molecule, a new
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zinc ions away from human insulin hexamers and simulta-
neously masks charges on the surface of the insulin
molecule. This causes the insulin hexamers to dissociate
and prevents re-association to the hexameric state upon s.c.
injection. This is achieved by the addition of EDTA and
citric acid. Using this approach, an ultra-fast insulin
formulation for s.c. injection was developed (VIAject;
Biodel, Danbury, CT, USA) [2]. The aim of this study
was to determine the pharmacodynamic and pharmacoki-
netic properties of this insulin in comparison to the same
dose of insulin lispro and human soluble insulin, and to
study the dose-responsive properties of this novel insulin at
two lower doses.
Methods
We recruited ten healthy volunteers (age 40 [19–61] years,
mean [range]; BMI 22.5 [19.2–24.9] kg/m
2) to this open-
label study that used five euglycaemic glucose clamps
(Biostator, mtb Medizintechnik, Ulm, Germany) with blood
glucose value 5 mmol/l and basal i.v. insulin infusion
0.15 mU kg
−1 min
−1 administered at 2 h before until 8 h
after glucose dose. The ethics committee of North Rhine in
Germany approved this Good Clinical Practice study. Using
a crossover study design with a fixed treatment order, 12 IU
human soluble insulin (Humulin R; Eli Lilly, Indianapolis,
IN, USA), 12 U insulin lispro (Humalog; Eli Lilly) and
12 IU of ultra-fast insulin (VIAject; Biodel) were injected
s.c. into the abdominal wall on three study days. On two
additional study days 6 and 3 IU of the ultra-fast insulin
were studied. This insulin was a re-constituted, lyophilised
regular human insulin. In this two-part formulation, the
insulin and diluent can be shipped and stored without
refrigeration. It is stable at room temperature and for at least
two years when refrigerated and frozen. Re-constitution
consists of withdrawing 10 ml of diluents with a syringe
and injecting it into the vial containing the lyophilised
insulin. Reconstitution yields a single, liquid 10 ml vial
(25 IU/ml) and in liquid form it should be refrigerated.
Glucose infusion rates (GIR) as determined by the glucose
clamp technique were the primary variable for analysis.
Sixth-order polynomialfunctionswerefittedtotheindividual
baseline-corrected GIR profiles to determine the following
pharmacodynamic summary measures: (1) maximum GIR
(GIRmax); (2) time to GIRmax (tGIRmax); (3) time to early/
late half-maximal GIRmax (tGIRmax+50% and tGIRmax−
50%); and (4) AUCGIR for specified time intervals.
The secondary variable was the serum insulin concen-
tration profile. From the insulin concentration over time
data the following pharmacokinetic variables were derived:
(1) maximum insulin concentration (Cmax); (2) time to Cmax
(tCmax); (3) time to 50% of Cmax (tCmax+50%); (4) time to
50% of Cmax after Cmax (tCmax−50%); and (5) the AUC of
insulin concentrations (AUCINS) for specified time inter-
vals. Human insulin serum concentrations (after adminis-
tration of human soluble insulin and ultra-fast insulin) were
measured by means of a commercial chemoluminescence
assay (catalogue number 2-001; MLT-Research, Cardiff,
UK). The assay sensitivity was 0.25 μU/ml. Insulin lispro
serum concentrations were measured by means of a lispro-
specific commercial RIA kit (catalogue number LPI-16K;
Linco Research, St Charles, MO, USA). Analyses were
performed by IKFE, Mainz, Germany. Pharmacokinetic
variables were calculated directly from the assayed values.
Since the assay employed for ultra-fast insulin and human
soluble insulin measured endogenous insulin and the
insulin administered at the glucose clamp procedure, the
measured levels were adjusted for baseline and any values
less than zero were set to zero. The respective pharmaco-
kinetic variables were calculated from the adjusted data as
follows: Cmax and tCmax were reported from the observed
adjusted maximum values, the early and late tCmax50%
were calculated by linear interpolation between the two
closest time points, and the AUC values were calculated
using the linear trapezoidal rule. As insulin lispro and ultra-
fastinsulin/humansolubleinsulinweremeasuredbydifferent
assays, no statistical analysis of concentration-dependent
variables was made.
Differences in pharmacokinetic and pharmacodynamic
variables were analysed (SAS version 8.02; SAS, Cary, NC,
USA) using one-way ANOVA followed by a two-tailed
Duncan’s multiple range test if the ANOVA showed
significance.
Results
Blood glucose levels during the glucose clamps were
comparable on the different study days as were their
swings. Specifically, blood glucose levels were: 12 IU
ultra-fast insulin 5.0±0.2 mmol/l (coefficient of variation
4.7%); 12 U insulin lispro 5.0±0.2 mmol/l (4.5%); 12 IU
human soluble insulin 4.9±0.4 mmol/l (7.7%); 6 IU ultra-fast
insulin 4.9±0.3 mmol/l (5.6%); and 3 IU ultra-fast insulin
4.9±0.2 mmol/l (4.6%).
Pharmacokinetic variables obtained with 12 IU of ultra-
fast insulin, insulin lispro and human soluble insulin
Figure 1a shows that subcutaneous injection of ultra-fast
insulin resulted in a more rapid increase in serum insulin
than did injection of insulin lispro, which, in turn was more
rapid than human soluble insulin. While the difference
between ultra-fast insulin and human soluble insulin was
significant, the difference between ultra-fast insulin and
Diabetologia (2008) 51:1602–1606 1603insulin lispro failed to reach statistical significance (tCmax)
(Table 1, Fig. 1a). The decline of serum insulin levels was
also more rapid with the ultra-fast insulin and insulin lispro.
Figure 1 also shows a normalised graph comparing the
different pharmacokinetic timing profiles. Serum C-peptide
levels showed a moderate decline from baseline levels after
s.c. injection of the different insulin formulations in all
cases, including the different doses of ultra-fast insulin
(data not shown).
Pharmacodynamic variables obtained with 12 IU of ultra-
fast insulin, insulin lispro and human soluble insulin The
pharmacodynamic properties of the three different insulin
formulations mirror the pharmacokinetic variables. Sub-
cutaneous injection of 12 IU ultra-fast insulin resulted in
a time–action profile characterised by a more rapid rise
in glucose consumption (tGIRmax+50%) in comparison to
12 U insulin lispro and 12 IU human soluble insulin
(Table 1, Fig. 1b). Maximal metabolic activity (tGIRmax)
was observed earlier and the metabolic activity in the
first 2 h after s.c. injection (AUCGIR 0–120) was higher
with ultra-fast insulin than with human soluble insulin,
but failed to reach statistical significance when compared
with insulin lispro. Maximal and total metabolic activity
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Fig. 1 Mean serum insulin profiles (a), normalised mean serum
insulin levels (b) and GIR profiles (c) after baseline correction
obtained after s.c. application of 12 IU human soluble insulin (dotted
lines), 12 U insulin lispro (bold lines) and 12 IU ultra-fast insulin
(non-bold lines) in ten healthy participants. (b) For normalisation of
the mean serum insulin levels the maximal serum insulin value
observed after s.c. injection with each of the three insulin formulations
was set as 100% and all other values were calculated as a proportion
of these. The dose–response relationship of the observed mean serum
insulin levels (d) and GIRs (e) with two additional doses of ultra-fast
insulin (6 IU, dashed lines; 3 IU, dotted lines) were also studied. To
convert GIR in mg kg
–1 min
–1 to μmol kg
–1 min
–1 multiply by 5.5
1604 Diabetologia (2008) 51:1602–1606(GIRmax; AUCGIR) were comparable with all three insulin
formulations.
Dose–response relationship The three dose levels of ultra-
fast insulin (3, 6 and 12 IU) showed the expected linear and
proportional increases in insulin absorption (Table 1,
Fig. 1c). In addition, the decline of late half-maximal levels
tended to be more rapid with 6 and 3 IU than with 12 IU.
With an increase in dose from 3 to 6 IU the AUCINS 0–
120 min increased by a factor of 1.92 and from 6 to 12 IU
by a factor of 1.56. The respective factors in the AUCGIR
0–120 min were 1.37 and 1.27.
The time to early half-maximal action, time to maximal
action and time to late half-maximal action after maximal
action were comparable with all three ultra-fast insulin
doses (Table 1, Fig. 1d). The maximal metabolic action
and the AUCs were different with the three different
doses.
Safety No serious adverse event occurred during this trial.
Adverse events were headache and injection site pain, each
reported by four participants (27%).
Discussion
This study showed that the ultra-fast insulin, VIAject, is
absorbed and exerts its action faster than either s.c.
injected human soluble insulin or insulin lispro at the
same dose. Further, the maximal and overall metabolic
effects of all three insulin formulations were comparable
at the same dose level, showing that when human insulin
is mixed with ingredients that lead the insulin molecule to
maintain the monomeric state and simultaneously mask
charges on its surface, an improvement in insulin
absorption and action is achieved. These observations in
healthy participants warrant confirmation in patients with
diabetes.
The pharmacodynamic response seen in the first hours
after s.c. administration of this novel human insulin
formulation came closer to that of physiological prandial
insulin secretion than do rapid-acting insulin analogues
such as lispro. The time to early half-maximal action is
15 min faster with insulin lispro than with human soluble
insulin; however, ultra-fast insulin is 32 min faster than
human soluble insulin and 17 min faster than insulin lispro.
It remains to be establishedb yd i r e c tm e a s u r e m e n t s
whether this led to a stronger suppression of hepatic gluco-
neogenesis, which helps to optimise postprandial metabolic
control [3].
During the first 2 h after administration, half the dose
of ultra-fast insulin produced a metabolic effect in the
same range as that achieved with 12 IU human soluble
insulin and insulin lispro over that period. Appropriately
designed clinical trials are now needed to establish
whether it is possible to meet prandial insulin require-
Table 1 Pharmacokinetic and pharmacodynamic summary measures of 12 IU human soluble insulin, 12 U insulin lispro and 12, 6 and 3 IU ultra-
fast insulin
Variable Human soluble insulin
(12 IU)
Insulin lispro
(12 U)
Ultra-fast insulin
(12 IU)
Ultra-fast insulin
(6 IU)
Ultra-fast insulin
(3 IU)
Pharmacokinetic
tCmax+50% (min) 37±22 26±10 18±18 7±3 12±13
tCmax (min) 120±70
a 66±34
a 60±43
a 51±48 54±44
tCmax−50% (min) 260±105
a 170±39
a 181±76
a 145±59 126±44
Cmax (pmol/l) 209±51 437±98 325±142
b 204±71
b 111±33
b
AUCINS 0–120 min ([nmol/l] × min) 13.8±3.2 36.2±7.9 26.9±9.6
b 17.3±4.6
b 9.0±2.9
b
AUCINS 0–480 min ([nmol/l] × min) 46.3±15.2 68.4±16.4 52.9±14.8
b 30.8±8.4
b 16.1±6.5
b
Pharmacodynamic
tGIRmax+50% (min) 66±15
c 51±13
c 33±17
c 35±17 31±14
tGIRmax (min) 193±57
d 152±30
d 136±56
d 115±32 111±41
tGIRmax−50% (min) 357±67 295±54 280±60 270±72 297±113
GIRmax (mg kg
−1 min
−1) 10.4±3.3 11.9±2.5 11.5±2.6
e 9.1±2.9
e 6.5±3.0
e
AUCGIR 0–120 min (mg/kg) 580±164
f 781±174
f 915±301
f,e 718±255
e 524±262
e
AUCGIR 0–480 min (mg/kg) 2993±1045 2977±753 2991±709
e 2223±717
e 1597±848
e
To convert GIR in mg kg
–1 min
–1 to μmol kg
–1 min
–1 multiply by 5.5 To convert AUCGIR in mg/kg to mmol/kg multiply by 5.5
aHuman soluble insulin>insulin lispro, ultra-fast insulin
b12 IU>6 IU>3 IU
cHuman soluble insulin>insulin lispro>ultra-fast insulin
dHuman soluble insulin>insulin lispro>ultra-fast insulin
e12 IU>6 IU>3 IU
fInsulin lispro, ultra-fast insulin>human soluble insulin
Diabetologia (2008) 51:1602–1606 1605ments as effectively with markedly reduced doses of ultra-
fast insulin (vs other insulins). Clearly, several clinically
relevant questions such as intra-individual variability of
the metabolic activity of ultra-fast insulin and the
effectiveness in controlling postprandial glycaemia remain
to be studied [4, 5].
In conclusion, this novel human insulin formulation
appears to be a promising candidate for improving post-
prandial glycaemic excursions with a reduced risk of late
postprandial hypoglycaemia.
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